middle.news
Acrux Targets $2.9B Female Testosterone Market with Co-Development Strategy
10:26am on Tuesday 28th of April, 2026 AEST
•
Healthcare
Read Story
Acrux Targets $2.9B Female Testosterone Market with Co-Development Strategy
10:26am on Tuesday 28th of April, 2026 AEST
Key Points
Strategic shift to Female Testosterone for HSDD
Phase I and II trials show safety and efficacy
Co-development planned to accelerate US approval
Existing topical generics portfolio supports R&D
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Acrux (ASX:ACR)
OPEN ARTICLE